诱导剂
体内
细胞凋亡
化学
癌细胞
程序性细胞死亡
脂质过氧化
GPX4
药物输送
癌症研究
癌症
药理学
生物
生物化学
氧化应激
生物技术
基因
遗传学
过氧化氢酶
有机化学
谷胱甘肽过氧化物酶
作者
Jing Wang,Hu Nan,Wenqian Xu,Linxi Zhao,Chutong Tian,Ken‐ichiro Kamei
标识
DOI:10.1016/j.bioorg.2024.107331
摘要
Ferroptosis represents a non-apoptotic form of programmed cell death characterized by iron-dependent lipid peroxidation. This cell death modality not only facilitates the direct elimination of cancer cells, but also enhances their susceptibility to other pharmacological anti-cancer agents. The burgeoning interest in ferroptosis has been driven by a growing body of evidence that underscores the efficiency and minimal toxicity of ferroptosis inducers. Traditional inducers, such as erastin and RSL3 have shown substantial promise in clinical applications due to their potent therapeutic effects. Their significant potential of these inducers has spurred the development of a variety of small molecule ferroptosis inducers. These novel inducers boast an enhanced structural variety, improved metabolic stability, the capability to initiate ferroptosis without triggering apoptosis, making them well-suited for in vivo use. Despite these advancements, challenges still remain, particularly concerning the drug delivery, tumor specificity, and circulation duration of these small molecules in vivo. Addressing these challenges, contemporary research has pivoted towards innovative delivery systems tailored for ferroptosis inducers to facilitate precise, targeted, and synegestic therapeutic delivery. This review scrutinizes the latest progress in small molecule ferroptosis inducers and nano drug delivery systems geared towards ferroptosis sensitization. Furthermore, it delineated the prospective therapeutic advantages and the existing hurdles in the development of ferroptosis inducers for malignant tumor treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI